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In this issue of the Netherlands Heart Journal, Gal et al. 
provide an analysis of patients included in the On-TIME II 
study, in which patients undergoing primary percutaneous 
coronary intervention for ST-elevation MI (STEMI) were 
randomly assigned to tirofiban or placebo treatment on top 
of usual medical treatment [7, 8]. The authors confirm the 
relation between AF and mortality in this setting and report 
the 30-day mortality in 830 patients without a previous his-
tory of AF, stratified by the moment of AF onset: (1) AF 
occurrence on the day of admission for MI, during which 
participants were continuously monitored; (2) AF between 
24 and 72 h after admission, with continuous monitoring 
for another 24 h (24–48 h) and a single electrocardiogram 
(ECG) the following day (48–72 h) and (3) AF > 72 h after 
admission, when ECGs were performed daily or whenever 
symptoms occurred. During follow-up, AF was detected in 
41 patients on the day of admission, in 14 in the subsequent 
48 h and in 18 in the last 27 days. This decreasing prevalence 
of AF may partially reflect the lower amount of AF monitor-
ing. The incident of new-onset AF was significantly associ-
ated with 30-day mortality when AF occurred on the day 
of admission. Three patients (7.3 %) died in the AF group, 
versus 17 in the non-AF group (2.2 %, p = 0.036). When AF 
occurred between 24–72 h after admission, mortality was 
14.3 and 1.4 % in the AF group and non-AF group, respec-
tively (p < 0.001). There was no association between AF and 
mortality when AF was diagnosed > 72h after admission, as 
no deaths were seen in the new-onset AF patients, but > 1 % 
of the patients without AF died.
The suggestion presented by Gal et al. that early- but not 
late-onset AF after MI is associated with increased mortality 
is interesting. However, the higher mortality in patients with 
AF < 72 h after admission cannot exclusively be ascribed 
to the timing of AF onset. First, a daily ECG is clearly less 
sensitive than continuous rhythm monitoring during the first 
New-onset atrial fibrillation (AF) occurs commonly follow-
ing myocardial infarction (MI) with an incidence ranging 
from 5 to 23 %. Unlike other complications of MI, such as 
cardiac failure or ventricular arrhythmias, it has long been 
underappreciated as a cause of adverse outcome [1, 2]. 
Indeed, several studies demonstrated an independent risk 
of AF on mortality, whereas others showed no significant 
independent effect, which may suggest that the simultane-
ous onset of AF and MI merely reflects the severity of the 
underlying disease. Interestingly, there are also reports of 
a beneficial effect of AF following MI on outcome [3–5]. 
Meta-analyses nevertheless consistently show that both pre-
existing AF and new-onset AF following MI independently 
increase the risk of mortality by 40–50 %, but controversy 
remains whether this altered risk relates to the pre-existence 
and type of AF, MI presentation or performed intervention 
[1, 6]. In 2011, a meta-analysis including 43 studies of in 
total 278,854 patients demonstrated a 46 % excess in mor-
tality in patients with AF after acute MI. A subgroup analy-
sis of nine studies that explicitly defined the new onset of 
AF showed similar results with an odds ratio (OR) of 1.37 
(95 % confidence interval: 1.26–1.49) for mortality [5]. In 
2012, a second meta-analysis even reported an OR of 3.38 
for patients with new-onset AF. Here, the risk of death was 
87 % higher for patients with new-onset AF compared with 
those with (possible) pre-existing AF, suggesting that the 
risk of mortality depends on the timing of AF onset.[1]
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48 h after admission. AF could therefore easily have been 
underdiagnosed during the second and especially the third 
period when mortality only occurred in patients presumed 
to be without AF. The investigators further did not adjust for 
the distinct differences at baseline between AF and non-AF 
patients regarding age, smoking, diabetes mellitus, history 
of MI and Killip classification. It is therefore well conceiv-
able that AF is not truly independent as a risk factor in this 
cohort. Potentially, biomarkers of underlying pathological 
processes could be collected in patients and mark the mech-
anisms leading to both AF and death. Understanding this 
could provide us with tools to anticipate on the increased 
risk of mortality in these patients; as for now, it remains 
unclear how to prevent AF-related death after MI.
In the current study, Gal et al. for the first time demon-
strate an association between early-onset AF after STEMI 
and mortality. The question remains unanswered whether 
the early onset of AF after MI should be regarded as an indi-
cator of preset misery or as a causal factor leading to mor-
tality. Until this issue is resolved, patients with early onset 
of AF after MI should be considered at increased risk, and 
where possible, extra care should be given to prevent a det-
rimental outcome.
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